Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer’s Wyeth Buy Rebuilds OTC Switch Potential

This article was originally published in The Tan Sheet

Executive Summary

Pfizer's proposed $68 billion acquisition of Wyeth brings the return of a consumer health division and with it a pipeline structure for potential Rx-to-OTC switches

You may also be interested in...



Merck Reaffirms Commitment To Consumer Care In Restructuring

Merck says it remains committed to retaining consumer care and animal health, though it continues to evaluate the businesses. Competitors such as Pfizer and Bristol-Myers Squibb successfully spun out non-pharma assets following similar restructurings.

Novartis Seems Close to Consumer Health Sale – Analyst

Novartis CEO Joe Jimenez made clear the firm is considering divesting its consumer product, animal health and vaccines and diagnostics business, Sanford and Bernstein analysts say. “It seems that Novartis will be making final decisions with these units fairly soon,” they say.

Novartis Seems Close to Consumer Health Sale – Analyst

Novartis CEO Joe Jimenez made clear the firm is considering divesting its consumer product, animal health and vaccines and diagnostics business, Sanford and Bernstein analysts say. “It seems that Novartis will be making final decisions with these units fairly soon,” they say.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS102561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel